Jonah Kallenbach spent the summer before his senior year with Anton, the hulking fluorescent supercomputer housed in the midtown Manhattan offices of hedge fund D.E. Shaw. Armed with 512 processors running in parallel, it’s been used since 2008 to probe some of the biggest questions in protein folding and structure.
Developing new medicines can take years of research and cost millions of dollars before they are even ready for clinical trials. Several biotech startups are using machine learning to revolutionize the process and get drugs into pharmacies more quickly. One of the newest is called Reverie Labs, which is part of Y Combinator’s latest batch. The Boston-based company wants to fix a critical bottleneck in the drug development process by speeding up the process of identifying promising molecules using recently published machine learning algorithms.